ClinicalTrials.gg
Enrolling by invitationNCT07829003VALID-ISTUpdated Sep 18, 2026

Validation of a Novel Incremental Step Test for Assessment of Cardiopulmonary Fitness and Ventilatory Thresholds in Adults

An interventional study of Cardiopulmonary Exercise Test and Incremental Step Test in Cardiorespiratory Fitness, Metabolic Health and Cardiac Function, sponsored by Heriot-Watt University. Enrolling by invitation at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-18.

Sponsored by Heriot-Watt University · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this single-group diagnostic validation and test-retest reliability study is to determine whether a novel Incremental Step Test (IST) can accurately assess cardiorespiratory fitness and ventilatory thresholds in healthy adults compared with an established laboratory-based cycle ergometer Cardiopulmonary Exercise Test (CPET). The main questions are whether the step test can elicit reliable physiological responses sufficient to identify the anaerobic threshold and respiratory compensation point, and whether it produces reproducible results when repeated under standardised conditions. The study will compare the incremental step test (IST) with CPET to assess whether the IST provides similar peak and submaximal physiological measures and agreement with CPET comparator. Participants will complete three laboratory exercise tests across separate visits: one maximal CPET on a cycle ergometer, followed by two repeated ISTs performed on a 25 cm step board following the audio metronome.

Read the detailed description

Participants will attend three laboratory visits separated by at least 3 days and conducted at similar times of the day. The first visit will include screening, anthropometric assessment, and a maximal CPET on an electronically braked cycle ergometer using a ramp protocol of 25 W/min for males and 20 W/min for females. Participants will complete 3 minutes of unloaded cycling followed by incremental protocol while maintaining the cadence at least 60 rpm, and the test will be terminated if they can no longer can sustain this cadence. Following CPET, participants will complete a 6-minute familiarisation session to practise the stepping activity, including the up-up-down-down stepping technique and alternation of the leading leg every 2 minutes. The second and third visits will involve repeated IST trials performed on 25 cm step board, with cadence progressed from 20 beats per minute and increased by 4 beats per minute every 20 seconds until volitional exhaustion. The IST will be terminated if the participant is unable to maintain the prescribed stepping rhythm for more than 15 seconds. Continuous breath-by-breath gas exchange, ECG, and heart rate monitoring will be used during testing to characterise peak performance and ventilatory threshold responses. Agreement between the step test and CPET, as well as test-retest reproducibility of the IST, will be evaluated to determine whether the new protocol could support more individualised exercise prescription in stepping-based activities.

02

Conditions studied

  • Cardiorespiratory Fitness
  • Metabolic Health
  • Cardiac Function
  • Pulmonary Function
  • Exercise Test

Keywords

  • Cardiopulmonary Exercise Testing
  • CPET
  • Exercise testing
  • Incremental Step Test
  • VO2 peak
  • Ventilatory threshold
  • reliability
  • validation
  • gas exchange
  • anaerobic threshold
03

In context

Lead sponsor

Heriot-Watt University is the lead sponsor of 5 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy adults aged 18 to 55 years.
  2. between 18.5 and 29.9 kg/m².
  3. Non-smoker.
  4. No known cardiovascular, respiratory, metabolic, neurological, or musculoskeletal conditions that would contraindicate maximal exercise testing.
  5. Able to provide written .
  6. Willing and able to complete one Cardiopulmonary Exercise Test and two Incremental Step Test sessions.

Exclusion criteria

Exclusion Criteria:

  1. Age younger than 18 years or older than 55 years.
  2. below 18.5 kg/m² or above 29.9 kg/m².
  3. Current smoker or use of nicotine products.
  4. Known cardiovascular, respiratory, metabolic, neurological, or musculoskeletal conditions that may affect exercise performance or make maximal exercise testing unsafe.
  5. Any to maximal exercise testing according to established exercise testing guidelines.
  6. Use of medications known to significantly affect cardiovascular, respiratory, or metabolic responses to exercise.
  7. Current injury, illness, or infection that may limit participation in exercise testing.
  8. Pregnancy.
  9. Inability to provide .
  10. Inability to complete study procedures or attend all required study visits.

    -

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Incremental Step Test Validation Protocol

    Participants will complete one laboratory-based Cardiopulmonary Exercise Test followed by two Incremental Step Test sessions conducted on separate visits. The first visit will include screening, anthropometric measurements, and a maximal incremental CPET on an electronically braked cycle ergometer using an individualised ramp protocol set at 25 W/min for males and 20 W/min for females, after 3 minutes of unloaded cycling. The second and third visits will involve two repeated incremental step tests on a standardised 25 cm step, with cadence starting at 20 beats per minute and increasing by 4 beats per minute every 20 seconds until volitional exhaustion. The CPET will be terminated if participants could not maintain a cadence of at least 60 rpm, and the step test will be terminated if participants could not maintain the prescribed stepping rhythm for 15 consecutive seconds. Exercise ECG, continuous heart rate, and breath-by-breath gas exchange will be recorded during all exercise tests.

    Diagnostic Test: Cardiopulmonary Exercise Test · Diagnostic Test: Incremental Step Test

Interventions

  • Diagnostic testCardiopulmonary Exercise Test

    A maximal incremental exercise test performed on a cycle ergometer with continuous breath-by-breath gas exchange and heart rate monitoring to assess cardiorespiratory fitness and physiological response

  • Diagnostic testIncremental Step Test

    A progressive step test using a standardised 25 cm step platform. Participants will complete a 3-minute warm-up at 20 beats per minute before cadence increases by 4 beats per minute every 20 seconds until volitional exhaustion or predefined termination criteria are reached.

06

What researchers measure

Primary outcomes

  1. Between-method agreement in oxygen uptake at Anaerobic Threshold (AT)

    Agreement between the Incremental Step Test and the established laboratory-based cycle ergometer Cardiopulmonary Exercise Test comparator for oxygen uptake at Anaerobic Threshold (mL/min), will be assessed using intraclass correlation coefficients and Bland-Altman analysis.

    Time frame: Baseline (Day 1-CPET) and IST assessments at Visits 2 and 3, scheduled at 3-7-day intervals.

  2. Between-method agreement in oxygen uptake at Respiratory Compensation Point (RCP)

    Agreement between the Incremental Step Test and the established laboratory-based cycle ergometer Cardiopulmonary Exercise Test comparator for oxygen uptake at Respiratory Compensation point / Ventilatory Threshold 2 (mL/min), will be assessed using intraclass correlation coefficients and Bland-Altman analysis.

    Time frame: Baseline (Day 1-CPET) and IST assessments at Visits 2 and 3, scheduled at 3-7-day intervals.

  3. Between-method agreement in Peak Oxygen Uptake (VO2peak)

    Peak oxygen uptake will be defined as the highest 30-second rolling average value recorded prior to test termination.

    Time frame: Baseline (Day 1-CPET) and IST assessments at Visits 2 and 3, scheduled at 3-7-day intervals.

Secondary outcomes

  1. Test-retest reliability of oxygen uptake at Anaerobic Threshold (AT)

    Test-retest reliability of oxygen uptake at AT (mL/min) derived from the Incremental Step Test (IST) between the first and second IST visits.

    Time frame: (Day 3-IST Visit 2) and IST Visit 3, scheduled 3-7 days apart.

  2. Test-retest reliability of oxygen uptake at Respiratory compensation point (RCP)

    Test-retest reliability of oxygen uptake at RCP (mL/min) derived from the Incremental Step Test (IST) between the first and second IST visits.

    Time frame: (Day 3-IST Visit 2) and IST Visit 3, scheduled 3-7 days apart.

07

Study locations

1 site
  • Oriam Scotlant Performance Centre
    Edinburgh, EH14 4AS, United Kingdom
08

References and documents

Individual participant data

Plan to share: No — No individual participant data will be shared publicly. The study will report findings using aggregated and de-identified data. Individual participant data will be retained securely by the research team in accordance with Heriot-Watt University research governance and data protection requirements.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07829003
Lead sponsor
Heriot-Watt University
Responsible party
David King (Assistant Professor, Heriot-Watt University) — Principal investigator
First posted
Sep 18, 2026
Start date
Jul 20, 2026
Primary completion
Sep 30, 2026 (estimated)
Completion
Oct 30, 2026 (estimated)
Last update
Sep 18, 2026

Study contacts

David King, BSc, MSc, PhD
principal investigator · Heriot-Watt University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion